The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

The analyst at Leerink expressed agreement with the market's positive reception to the drug's prospects for HIV pre-exposure prophylaxis ... as sales of Biktarvy, its leading HIV drug, are ...

Biktarvy is the number one prescribed regimen ... approved for the treatment of HIV-1 infection and PrEP. The strong results increase the probability of lenacapavir’s approval that should ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

Last week, the Biktarvy maker tapped six generic manufacturers ... The company has estimated that the HIV PrEP market will more than double in size to around 4 billion pounds to 5 billion pounds ...